Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 31, 2020
Reporting Period: Specific event date of December 31, 2020.
This filing reports a corporate governance event regarding the amendment of an existing securities sales agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the amendment of the Company's At Market Issuance Sales Agreement (originally dated July 27, 2018, and previously amended on July 20, 2020). The amendment adds H.C. Wainwright & Co., LLC as an additional agent to the existing group of agents, which includes B. Riley Securities, Inc., Cantor Fitzgerald & Co., National Securities Corporation, and Oppenheimer & Co. Inc.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding financial performance or strategic direction beyond the execution of the agreement amendment.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Unusual Items: None reported.
Key Facts for Investor Verification
- Verify the terms of Amendment No. 2 to the At Market Issuance Sales Agreement attached as Exhibit 1.1.
- Confirm the role and compensation structure of the newly added agent, H.C. Wainwright & Co., LLC.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial figures.
- Check for any subsequent filings regarding the utilization of the amended sales agreement.